Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   41200   clinical trials with a EudraCT protocol, of which   6743   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-002579-83
    Sponsor's Protocol Code Number:54767414LUC2001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2016-11-11
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-002579-83
    A.3Full title of the trial
    A Phase 1b/2, Open-Label, Randomized Study of Daratumumab Administered in Combination with Atezolizumab Compared with Atezolizumab Alone in Subjects with Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer
    Estudio de fase 1b/2, abierto y aleatorizado, comparativo de daratumumab administrado en combinación con atezolizumab frente a atezolizumab solo en sujetos con cáncer de pulmón no microcítico avanzado o metastásico tratado previamente
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study of Daratumumab combined with Atezolizumab versus Atezolizumab in Previously Treated Subjects with Advanced Non-Small Cell Lung Cancer.
    Estudio de daratumumab combinado con atezolizumab frente a atezolizumab en sujetos con cáncer de pulmón no microcítico avanzado o metastásico tratados previamente
    A.3.2Name or abbreviated title of the trial where available
    CALLISTO
    A.4.1Sponsor's protocol code number54767414LUC2001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen-Cilag International NV
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Research & Development
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationPAREXEL International S.L.
    B.5.2Functional name of contact pointPC-CTRS
    B.5.3 Address:
    B.5.3.1Street AddressEdificio Sollube- Plaza de Carlos Trías Bertrán, 7 - 7ª plta.
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28020
    B.5.3.4CountrySpain
    B.5.4Telephone number+3491 391 3443
    B.5.5Fax number+34913914925
    B.5.6E-mailclinicaltrial.enquiries@PAREXEL.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDaratumumab
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNDARATUMUMAB
    D.3.9.1CAS number 945721-28-8
    D.3.9.2Current sponsor codeJNJ-54767414 (Daratumumab)
    D.3.9.3Other descriptive nameHUMAX-CD38
    D.3.9.4EV Substance CodeSUB175772
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typehuman monoclonal antibody
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name TECENTRIQ
    D.2.1.1.2Name of the Marketing Authorisation holderGenentech
    D.2.1.2Country which granted the Marketing AuthorisationUnited States
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameAtezolizumab
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNATEZOLIZUMAB
    D.3.9.2Current sponsor codeRO5541267
    D.3.9.4EV Substance CodeSUB178312
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1200
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
    Cáncer de pulmón no microcítico avanzado o metastásico
    E.1.1.1Medical condition in easily understood language
    A specific type of lung cancer called "Non-Small Cell Lung Cancer"
    Un tumor especifico de cancer llamado "cáncer de pulmón no microcítico"
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level PT
    E.1.2Classification code 10029522
    E.1.2Term Non-small cell lung cancer stage IV
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 19.0
    E.1.2Level PT
    E.1.2Classification code 10029521
    E.1.2Term Non-small cell lung cancer stage IIIB
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare the overall response rate (ORR) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone.
    Comparar la tasa de respuesta global (ORR, overall response rate) en sujetos tratados con daratumumab en combinación con atezolizumab frente a atezolizumab solo.
    E.2.2Secondary objectives of the trial
    - To assess the safety of the combination of daratumumab and atezolizumab
    - To compare the duration of response (DoR) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone
    - To compare the clinical benefit rate (CBR) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone
    - To compare progression-free survival (PFS) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone
    - To compare overall survival (OS) in subjects treated with daratumumab in combination with atezolizumab versus atezolizumab alone
    - To evaluate the pharmacokinetic and immunogenicity profile of daratumumab when given in combination with atezolizumab
    - To evaluate the pharmacokinetic and immunogenicity profile of atezolizumab when given in combination with daratumumab
    - Evaluar la seguridad de la combinación de daratumumab y atezolizumab
    - Comparar la duración de la respuesta (DoR, duration of response) en sujetos tratados con daratumumab en combinación con atezolizumab frente a atezolizumab solo
    - Comparar la tasa de beneficio clínico (CBR, clinical benefit rate) en sujetos tratados con daratumumab en combinación con atezolizumab frente a atezolizumab solo
    - Comparar la supervivencia sin progresión (PFS, progression-free survival) en sujetos tratados con daratumumab en combinación con atezolizumab frente a atezolizumab solo
    - Comparar la supervivencia global (OS, overall survival) en sujetos tratados con daratumumab en combinación con atezolizumab frente a atezolizumab solo
    - Evaluar el perfil farmacocinético y la capacidad inmunógena del daratumumab en su administración en combinación con atezolizumab
    - Evaluar el perfil farmacocinético y la capacidad inmunógena del atezolizumab en su administración en combinación con daratumumab
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. ≥18 years of age
    2. ECOG performance status of 0 or 1.
    3. Have histologically or cytologically confirmed advanced or metastatic NSCLC (Stage IIIb or IV).
    4. Measurable disease, as defined by RECIST v1.1.
    5. Known PD-L1 tumor status as determined by an IHC assay performed by the central laboratory on tissue obtained at Screening.
    6. Specific laboratory results obtained within 14 days prior to first administration of study drug.
    7. A woman of childbearing potential must have a negative highly sensitive serum (b-human chorionic gonadotropin [b-hCG]) at Screening within 14 days prior to study drug administration.
    8. Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive methods for subject participating in clinical studies.
    9. During the study and for a minimum of approximately 3 months after the last dose of daratumumab or 5 months after the last dose of atezolizumab, in addition to the highly effective method of contraception, a man
    - who is sexually active with a woman of childbearing potential must agree to use a barrier method of contraception (eg, condom with spermicidal foam/gel/film/cream/suppository)
    - who is sexually active with a woman who is pregnant must use a condom
    - must agree not to donate sperm.
    10. Willing and able to adhere to the prohibitions and restrictions specified in this protocol.
    11. Must sign an informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study.
    1. Edad >=18 años.
    2. Estado funcional del ECOG de 0 o 1.
    3. Cáncer de pulmón no microcítico avanzado o metastásico confirmado histológica o citológicamente (estadio IIIb o IV).
    4. Enfermedad medible según la definición de los RECIST v1.1.
    5. Situación tumoral en cuanto a PD-L1 conocida mediante análisis inmunohistoquímico realizado en el laboratorio central con tejido obtenido en la selección.
    6. Resultados requeridos de los análisis de laboratorio obtenidos en el plazo de los 14 días previos a la primera administración del fármaco del estudio.
    7. En el caso de las mujeres potencialmente fértiles, resultado negativo de una prueba ultrasensible de embarazo en suero (betagonadotropina coriónica humana [b-hCG]) en la selección, realizada en el plazo de los 14 días previos a la administración del fármaco del estudio.
    8. Cumplimiento de los requisitos de anticoncepción por los hombres y las mujeres, en conformidad con la normativa local sobre uso de métodos anticonceptivos por los sujetos participantes en ensayos clínicos.
    9. Durante el estudio y como mínimo hasta aproximadamente 3 meses después de la última dosis de daratumumab o 5 meses después de la última dosis de atezolizumab, además de utilizar un método anticonceptivo de alta eficacia, los hombres
    - que mantengan relaciones sexuales con mujeres potencialmente fértiles deben comprometerse a utilizar un método anticonceptivo de barrera (por ejemplo, preservativo con espermicida en espuma, gel, película, crema u óvulo).
    - que mantengan relaciones sexuales con mujeres embarazadas deben utilizar preservativo.
    - deben comprometerse a no donar semen.
    10. Voluntad y capacidad de respetar las prohibiciones y restricciones especificadas en el protocolo.
    11. Firma del documento de consentimiento informado para indicar que el sujeto comprende la finalidad del estudio y los procedimientos que este exige y que está dispuesto a participar en el estudio.
    E.4Principal exclusion criteria
    1. Received any of the following prescribed medications or therapies in the past:
    - Anti-CD38 therapy, including daratumumab
    - CD137 agonists, immune checkpoint inhibitors including but not limited to anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapies
    2. Received any of the following prescribed medications or therapies within the specified period:
    - Approved anti-cancer therapy, including chemotherapy, within 3 weeks prior to initiation of study treatment.
    - Other investigational agent or participation in another clinical study with therapeutic intent within 28 days or 5 half-lives of the investigational agent (whichever is longer) to enrollment.
    - Use of systemic corticosteroids ≤2 weeks before Cycle 1 Day 1.
    - Use of systemic corticosteroids ≤10 mg/day prednisone equivalent, or acute use of higher equivalent doses may be allowed with Medical Monitor approval.
    3. Has any of the following conditions:
    - Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging (MRI) evaluation during Screening and prior radiographic assessments.
    - Leptomeningeal disease or spinal cord compression not definitively treated with surgery or radiation
    - Uncontrolled tumor-related pain
    4. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently); indwelling catheters are allowed.
    5. Malignancies other than NSCLC within 2 years prior to randomization, with the exception of carcinoma in situ of the cervix or breast, basal or squamous-cell skin cancer, or other malignancy that in the opinion of the investigator and Sponsor’s Medical Monitor is considered cured with a minimal risk of recurrence within 5 years.
    6. History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener’s granulomatosis, Sjögren’s syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.
    7. History of idiopathic pulmonary fibrosis, organizing pneumonia (eg, bronchiolitis obliterans), druginduced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted.
    8. Known chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) <50% of predicted normal. Note that FEV1 testing is required for subjects suspected of having COPD and subjects must be excluded if FEV1 <50% of predicted normal.
    9. Known to be seropositive for human immunodeficiency virus (HIV)
    10. Active hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg] or antibodies to hepatitis B surface and core antigens [anti-HBs and anti-HBc, respectively]) or hepatitis C (anti-HCV antibody positive or HCV-RNA quantitation positive).
    11. Severe infections (including active tuberculosis) within 1 week prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia
    12. Screening QTc interval >470 ms.
    13. Clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from Day 1 of study drug administration, New York Heart Association Class III or IV congestive heart failure, and arrhythmia requiring therapy.
    14. Prior allogeneic bone marrow transplantation or solid organ transplant.
    15. Administration of a live, attenuated vaccine within 4 weeks before first study agent administration.
    16. Women who are pregnant, lactating, or intending to become pregnant during the study or within at least 3 months after last dose of daratumumab or 5 months after the last dose of atezolizumab; men who intend to father a child during the study or within at least 3 months after the last dose of daratumumab or 5 months after the last dose of atezolizumab.
    17. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.
    18. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the daratumumab or atezolizumab formulation.
    19. Any other concurrent medical or psychiatric condition, diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or render the subject at high risk from treatment complications.
    1. Haber recibido alguna vez cualquiera de los siguientes medicamentos o tratamientos:
    - Tto anti-CD38, incluido el daratumumab
    - Tto con agonistas de CD137, inhibidores de los puntos de control inmunitario, tales como, anti-CTLA-4, anti-PD-1 y anti-PD-L1
    2. Haber recibido cualquiera de los siguientes medicamentos o ttos en el periodo señalado:
    - Ttos antineoplásicos aprobados, incluida quimioterapia, en el plazo de las 3 semanas previas al inicio del tto del estudio.
    - Otro producto en investigación o participación en otro ensayo con intención terapéutica en el plazo de los 28 días o 5 semividas de dicho producto en investigación (eligiéndose el mayor de estos plazos) anteriores a la inclusión.
    - Corticosteroides sistémicos ≤2 semanas antes del día 1 del ciclo 1.
    - Con la aprobación del monitor médico, se podrá permitir el uso de corticosteroides sistémicos en dosis equivalentes a ≤10 mg/día de prednisona, o su uso en ttos cortos con dosis mayores.
    3. Presencia de cualquiera de los procesos siguientes:
    - Metástasis en el SNC activas o no tratadas, a juzgar por los estudios de TC o RM realizados durante la selección y las evaluaciones radiológicas previas.
    - Enfermedad leptomeníngea o compresión de médula espinal no sometida a tto definitivo mediante cirugía o radioterapia.
    - Dolor de origen tumoral no controlado.
    4. Derrame plural no controlado, derrame pericárdico o ascitis que precisen drenajes repetidos (una vez al mes o más frecuentes); se permiten los catéteres permanentes.
    5. Neoplasias malignas distintas del CPNM en el plazo de los 2 años previos a la aleatorización, excepto el carcinoma in situ de cuello uterino o mama, el cáncer cutáneo basocelular o espinocelular, u otra neoplasia maligna que se considere curada y de mínimo riesgo de recidiva en un plazo de 5 años, a juicio del investigador y el monitor médico del promotor.
    6. Antecedentes de enfermedades autoinmunitarias, tales como, miastenia grave, miositis, hepatitis autoinmunitaria, LES, AR, enfermedad inflamatoria intestinal, trombosis vascular asociada a síndrome antifosfolipídico, granulomatosis de Wegener, síndrome de Sjögren, síndrome de Guillain-Barré, esclerosis múltiple, vasculitis o glomerulonefritis.
    7. Antecedentes de fibrosis pulmonar idiopática, neumonía organizada (por ejemplo, bronquiolitis obliterante), neumonitis medicamentosa, neumonitis idiopática o signos de neumonitis activa en la TC de tórax de la selección; se permiten los antecedentes de neumonitis por radiación en el campo irradiado (fibrosis).
    8. Diagnóstico de EPOC con un volumen respiratorio forzado en el primer segundo (FEV1) <50% del valor normal predicho. Téngase en cuenta que se requiere determinar el FEV1 en los sujetos con sospecha de EPOC y que deberá excluirse al sujeto si presenta un resultado de FEV1 <50% del valor normal predicho.
    9. Seropositividad del VIH.
    10. Hepatitis B activa o hepatitis C
    11. Infecciones graves (incluida la tuberculosis activa) en el plazo de 1 semana antes del inicio del tto del estudio, tales como, entre otros casos, hospitalización por complicaciones de infección, bacteriemia o neumonía grave.
    12. Intervalo QTc >470 ms en la selección.
    13. Cardiopatía de importancia clínica, como angina inestable, infarto de miocardio agudo en el plazo de los 6 meses anteriores al primer día de administración del fármaco del estudio, insuficiencia cardiaca congestiva de clase III o IV de la New York Heart Association y arritmia que requiera tratamiento.
    14. Antecedentes de alotraplante de médula ósea o trasplante de órgano sólido.
    15. Administración de vacunas de microorganismos vivos atenuados en el plazo de las 4 semanas anteriores a la primera administración del fármaco del estudio.
    16. Mujeres embarazadas, en periodo de lactancia o que tengan intención de quedarse embarazadas durante el estudio o hasta 3 meses después de la última dosis de daratumumab o 5 meses después de la última dosis de atezolizumab; hombres que tengan intención procrear durante el estudio o hasta 3 meses después de la última dosis de daratumumab o 5 meses después de la última dosis de atezolizumab.
    17. Antecedentes de reacciones alérgicas graves, anafilácticas u otras reacciones de hipersensibilidad a anticuerpos quiméricos o humanizados o a proteínas de fusión.
    18. Hipersensibilidad o alergia conocidas a biofármacos producidos en células de ovario de hámster chino o a cualquier componente de la formulación de daratumumab o atezolizumab.
    19. Cualquier otro proceso o enfermedad médica o psiquiátrica o disfunción metabólica concomitante, o sospecha fundada —según los hallazgos de la exploración física o los resultados de los análisis clínicos— de enfermedad o proceso que contraindique el uso de un fármaco en investigación o que pueda influir en la interpretación de los resultados del estudio o que conlleve para el sujeto gran riesgo de complicaciones del tto.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint is ORR: the proportion of subjects with a partial response (PR) or complete response (CR) as defined by RECIST v1.1 response criteria
    El criterio principal de valoración es la tasa de respuesta global: porcentaje de sujetos con respuesta parcial (PR, partial response) o respuesta completa (CR, complete response) según los criterios de
    respuesta RECIST v1.1
    E.5.1.1Timepoint(s) of evaluation of this end point
    Throughout the whole study.
    Durante todo el estudio.
    E.5.2Secondary end point(s)
    - Incidence of adverse events
    - DoR: the duration from the date of the initial documentation of a response to the date of the first objectively documented evidence of recurrence or progressive disease or death, whichever status is recorded first.
    - CBR: the proportion of subjects who achieve disease control (CR, PR, or SD with duration of at least 16 weeks).
    - PFS: the duration from the date of randomization to the date of objectively documented progression or death due to any cause, whichever status is recorded first.
    - OS: the duration from the date of randomization to the date of death due to any cause.
    - Serum daratumumab concentration (Cmin, Cmax) and incidence of anti-daratumumab antibodies
    - Serum atezolizumab concentration (Cmin, Cmax) and incidence of anti-atezolizumab antibodies
    - Incidencia de acontecimientos adversos
    - Duración de la respuesta: tiempo que transcurre desde la fecha en la que se documenta por primera vez una respuesta hasta la fecha en que se documenta de manera objetiva el primer signo de recidiva
    o enfermedad progresiva o hasta la fecha de la muerte, eligiéndose entre estas circunstancias la que se registre en primer lugar.
    - Tasa de beneficio clínico: porcentaje de sujetos que alcanzan el control de la enfermedad (respuesta completa, respuesta parcial o enfermedad estable [SD, stable disease] durante al menos 16 semanas).
    - Supervivencia sin progresión: tiempo que transcurre desde la fecha de la aleatorización hasta la fecha en que se documenta de forma objetiva la progresión o hasta la fecha de la muerte por cualquier
    causa, eligiéndose entre estas dos circunstancias la que se registre en primer lugar.
    - Supervivencia global: tiempo transcurrido desde la fecha de la aleatorización hasta la fecha de la muerte por cualquier causa.
    - Concentraciones séricas de daratumumab (Cmin, Cmax) e incidencia de anticuerpos anti-daratumumab
    - Concentraciones séricas de atezolizumab (Cmin, Cmax) e incidencia de anticuerpos anti-atezolizumab
    E.5.2.1Timepoint(s) of evaluation of this end point
    Throughout the whole study.
    Durante todo el estudio.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) Yes
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other Yes
    E.7.1.3.1Other trial type description
    Satefy run-in cohort to assess safety/tolerability of atezolizumab administered with daratumumab
    Preinclusión de seguridad para medir seguridad/tolerabilidad de atezolizumab administrada con daratu
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned14
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA37
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    France
    Germany
    Hungary
    Spain
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last patient last visit.
    Ultima visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 38
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 58
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 69
    F.4.2.2In the whole clinical trial 96
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No post-trial medication will be provided, the further treatment of patients after end of trial will be carried out according to their physicians' decision.
    No se proporcionará medicación posterior al ensayo, los futuros tratamientos del paciente despues del final del ensayo, se llevarán a cabo de acuerdo con la decision de su medico.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-02-24
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-12-21
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-09-26
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA